GNPXGenprex Inc
GNPX
Genprex Inc14,652
Mkt Cap
$7.72MVolume
100,985.0052W High
$63.0052W Low
$2.61PE Ratio
-0.07GNPX Fundamentals
Price
$3.24Prev Close
$3.33Open
$3.3250D MA
$7.57Beta
1.24Avg. Volume
298,170.16EPS (Annual)
-$266.95P/B
4.36Rev/Employee
$0.00Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer...
PR Newswire·17d ago
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials PR Newswire AUSTIN...
PR Newswire·22d ago
Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1...
PR Newswire·23d ago
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Announces European Patent Office's Intent...
PR Newswire·1mo ago
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market...
PR Newswire·1mo ago
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and...
PR Newswire·1mo ago
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market...
PR Newswire·2mo ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...
PR Newswire·2mo ago